Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...
Thirty years ago today, Netscape Communications and Sun Microsystems issued a joint press release announcing JavaScript, an object scripting language designed for creating interactive web applications ...
Chinese tech giant Baidu launched its new flagship AI model, ERNIE 5.0, in Beijing on Thursday. The company unveiled the system at its Baidu World 2025 event. It is built to handle text, images, audio ...
The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...
18 popular NPM packages with over 2 billion weekly downloads were compromised through a phishing attack targeting developer “Qix” The malware functioned as a “crypto-clipper,” silently replacing ...
Sept 2 (Reuters) - Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results